UBR5 and mantle cell lymphoma: However, deletion of FBXO25 [9], mutation of UBR5 [10] or, as suggested here, a decreased of global 26S proteasome activity modify the UPS and in turn, the sensitivity to drugs and the clinical response of MCL patients.